Generics - Watson Pharmaceuticals

Filter

Current filters:

Watson Pharmaceuticals

Popular Filters

1 to 25 of 61 results

Shire prevails in US Lialda patent dispute with Watson

10-05-2013

Ireland-headquartered drugmaker Shire's (LSE: SHP) subsidiary Shire Development has prevailed in its…

ActavisGastro-intestinalsGenericsLegalLialdaNorth AmericaPatentsPharmaceuticalShireWatson Pharmaceuticals

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26-04-2013

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

AstraZeneca in Crestor patent settlement with Actavis and EGIS Pharma

25-03-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into a settlement agreement in its US patent…

ActavisCardio-vascularCrestorGenericsNorth AmericaPatentsPharmaceuticalrosuvastatinShionogiWatson Pharmaceuticals

Lower 4th-qtr 2012 profits at Actavis but beat expectations

19-02-2013

US generics major Actavis (NYSE: ACT, the new name for the Watson business) reported net revenue increased…

ActavisFinancialGenericsWatson Pharmaceuticals

Pfizer prevails in Rapamune patent dispute with Watson

01-02-2013

Global pharma behemoth Pfizer (NYSE: PFE) says that the US District Court for the District of Delaware…

ActavisGenericsImmunologicalsLegalNorth AmericaPatentsPfizerPharmaceuticalRapamuneWatson Pharmaceuticals

Watson Pharma now trading as Actavis; Dr Reddy's debuts generic Clarinex Reditabs in USA

28-01-2013

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) announced last week that the company has adopted…

ActavisClarinex ReditabsDr Reddy's LaboratoriesFinancialGenericsManagementMarkets & MarketingWatson Pharmaceuticals

Watson acquires Uteron Pharma; confirms Opana patent challenge

24-01-2013

US generic and specialty drugmaker Watson Pharmaceuticals (NYSE: WPI) says that it has completed the…

Endo PharmaceuticalsGenericsGrunenthalMergers & AcquisitionsNeurologicalNorth AmericaOpanaPatentsPharmaceuticalUteron PharmaWatson PharmaceuticalsWomen's Health

Patent cliff: one drugmaker's sorrow is another one's joy

20-01-2013

The patent cliff has seen many drug majors lose their exclusivity on blockbuster drugs to generic makers…

DilantinGenericsLystedaMarkets & MarketingMylan LaboratoriesNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

US Supreme Court agrees to review pay-for-delay generic deals

10-12-2012

The US Supreme Court has agreed to a request by the Federal Trade Commission to look into the practice…

GenericsLegalNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

Watson gains FDA approval for generic Revatio

12-11-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has received approval from the US Food and Drug…

GenericsNorth AmericaPfizerRegulationRespiratory and PulmonaryRevatioWatson Pharmaceuticals

Watson 3rd-qtr EPS jumps 24%, as revenues rise 19%

01-11-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has reported that net income for the third quarter…

ActavisFinancialGenericsWatson Pharmaceuticals

Watson gets FDA final approval for generic Actos; negative news on Prochieve appeal

29-10-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) said on Friday that it has launched a generic…

ActosDiabetesGenericsLegalMylan LaboratoriesNorth AmericaProchieveRegulationReproductiveTakeda PharmaceuticalsWatson Pharmaceuticals

Forest Labs links with moksha8 for Viibryd in Latin America; Watson sells minority stake

24-10-2012

US drugmaker Forest Laboratories (NYSE: FRX) has entered into a broad strategic alliance with Brazil-based…

Forest LaboratoriesGenericsLicensingMergers & AcquisitionsMoksha8NeurologicalPharmaceuticalSouth AmericaViibrydWatson Pharmaceuticals

US FTC puts divestment conditions on Watson's acquisition of Actavis

16-10-2012

The USA's Federal Trade Commission will require Watson Pharmaceuticals (NYSE: WPI) and fellow generic…

ActavisGenericsLegalMergers & AcquisitionsNorth AmericaNovartisPar PharmaceuticalsSandozWatson Pharmaceuticals

Watson gets FDA approval for generic Sanctura XR and Avapro

14-10-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has received approval from the US Food and Drug…

AllerganAvaproCardio-vascularGenericsGenito-urinaryNorth AmericaRegulationSanctura XRSanofiWatson Pharmaceuticals

FTC seeks US Supreme Court review in AndroGel "pay-for-delay" case

08-10-2012

At the request of the US Federal Trade Commission, the Solicitor General of the USA petitioned the country's…

Abbott LaboratoriesAndroGelGenericsLegalMen's HealthNorth AmericaPatentsPharmaceuticalSolvayWatson Pharmaceuticals

Watson sues US FDA regarding generic Actos approval delay

16-08-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) says it has filed suit against the US Food and…

ActosDiabetesGenericsLegalNorth AmericaTakeda PharmaceuticalsWatson Pharmaceuticals

Watson debuts generic Nexium in Europe; Mylan launches Amidate copy in USA

08-08-2012

US generics firm Watson Pharmaceuticals (NYSE: WPI) said yesterday that its third-party business Specifar…

AmidateAstraZenecaEuropeGastro-intestinalsGenericsHospiraMarkets & MarketingMylan LaboratoriesNeurologicalNexiumNorth AmericaRegulationWatson Pharmaceuticals

1 to 25 of 61 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top